Celecoxib / MRP1 Cancer Research Results

CEL, Celecoxib: Click to Expand ⟱
Features: NSAID
Celecoxib inhibits the formation of prostaglandins: used primarily to treat pain and other symptoms of osteoarthritis, rheumatoid arthritis, joint and musculoskeletal conditions.

Celecoxib is a diaryl-substituted selective cyclooxygenase-2 inhibitor that lowers prostaglandin synthesis and is used clinically as an oral nonsteroidal anti-inflammatory drug. It is formally classified as a small-molecule NSAID and COX-2–preferential inhibitor. Standard abbreviations include celecoxib and CEL. In oncology, its main rationale is suppression of the COX-2/PGE2 inflammatory-tumor axis, with additional COX-2-independent effects reported at higher experimental concentrations, including interference with PDK1/Akt signaling, ER calcium handling, and stress-linked apoptosis pathways. Nestronics lists it as an NSAID and currently indexes mainly EMT, HIF-1α/VEGF, COX-2, NF-κB, p65, and TGF-β/SMAD3-related findings.

Primary mechanisms (ranked):

  1. COX-2 inhibition with reduced PGE2 signaling and downstream inflammatory, proliferative, angiogenic, and immune-evasive tumor support
  2. Suppression of NF-κB-linked inflammatory survival programs
  3. Reduction of hypoxia/angiogenesis signaling including HIF-1α and VEGF in relevant models
  4. Partial inhibition of PDK1/Akt survival signaling in some tumor systems
  5. COX-2-independent ER stress and Ca²⁺ dysregulation via SERCA-related effects at supratherapeutic or high in-vitro concentrations
  6. Contextual chemosensitization, including effects on apoptosis threshold and in some reports drug-resistance programs such as P-gp
  7. Possible ancillary carbonic anhydrase inhibition is mechanistically interesting but not established as the dominant clinical anticancer mechanism

Bioavailability / PK relevance: Celecoxib is orally active. Peak plasma levels occur at about 3 hours, effective half-life is about 11 hours, steady state is reached by about day 5, and the drug is highly protein bound. Exposure is roughly dose-proportional up to 200 mg twice daily, with less-than-proportional increases above that range because of solubility limits. It is metabolized mainly by CYP2C9, so poor metabolizers and strong CYP2C9 interactions are clinically relevant.

In-vitro vs systemic exposure relevance: This is an important translation constraint. Many direct pro-apoptotic, SERCA/ER-stress, and stronger Akt-related anticancer effects are reported in vitro at concentrations commonly above those readily achievable with standard anti-inflammatory dosing. By contrast, COX-2/PGE2 suppression is clearly clinically reachable and is the most exposure-plausible core mechanism. Therefore, low- to mid-micromolar inflammatory and microenvironment effects are more translatable than high-concentration cytotoxic claims.

Clinical evidence status: Strong clinical deployment exists for pain/inflammatory indications, not for cancer treatment. In oncology, evidence is mixed: extensive preclinical support, some small human and adjunct studies, but major randomized adjuvant trials in unselected breast and stage III colon cancer were negative overall. A more recent biomarker-defined signal has emerged in PIK3CA-activated stage III colon cancer, where celecoxib appeared beneficial in subgroup analysis, so any cancer role currently looks biomarker- and context-dependent rather than broadly established.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 COX-2 / PGE2 inflammatory signaling COX-2 activity ↓; PGE2 tone ↓; proliferation, survival, invasion, immune evasion ↓ Inflammatory prostaglandin signaling ↓ R/G Core anti-inflammatory antitumor mechanism Best-supported and most clinically reachable mechanism; strongest translational anchor for oncology repurposing
2 NF-κB inflammatory survival axis NF-κB/p65 ↓; inflammatory survival transcription ↓ Inflammatory signaling ↓ R/G Reduced survival and inflammatory tone Consistent with Nestronics and broader literature; partly downstream of reduced PGE2 but may also reflect parallel signaling effects
3 HIF-1α / VEGF angiogenesis axis HIF-1α ↓; VEGF ↓; angiogenic support ↓ ↔ or angiogenic signaling ↓ in inflammatory settings G Antiangiogenic pressure Likely relevant in hypoxic and COX-2-high tumors; fits both Nestronics indexing and broader COX-2/PGE2 biology
4 TGF-β / SMAD3 / EMT TGF-β ↓; SMAD3 ↓; EMT ↓; migration/invasion ↓ ↔ G Anti-migratory and anti-invasive effect Nestronics support is specific here; likely more tumor-contextual than universally dominant
5 PDK1 / Akt survival signaling PDK1/Akt ↓ (context-dependent); apoptosis threshold ↓ ↔ R/G COX-independent survival suppression Mechanistically important in the celecoxib literature, but many strong effects are reported at higher in-vitro concentrations
6 Ca²⁺ homeostasis and ER stress ER Ca²⁺ reuptake ↓; cytosolic Ca²⁺ stress ↑; ER stress/apoptosis ↑ Potential stress if exposure is high enough P/R Stress-triggered apoptosis Usually linked to SERCA interference and considered mainly a high-concentration or COX-independent mechanism
7 Mitochondrial apoptosis program Caspase activation ↑; Bcl-2-family survival balance shifts toward apoptosis ↔ R/G Apoptotic execution Generally downstream of Akt inhibition, ER stress, or combined treatment sensitization rather than the first initiating event
8 Chemosensitization Drug sensitivity ↑; apoptosis with cytotoxics ↑ Potential inflammation/pain benefit in host context G Adjunctive therapy potential Observed preclinically and in some clinical adjunct settings, but not confirmed as a broad survival-improving strategy in unselected populations
9 P-gp and resistance signaling P-gp ↓ (model-dependent); intracellular drug retention ↑ ↔ G Possible reversal of drug resistance Interesting but not core; should be treated as secondary and context-specific
10 Carbonic anhydrase inhibition CA-related pH adaptation ↓ (context-dependent) Off-target CA interaction possible ↔ Ancillary microenvironment effect Celecoxib can inhibit carbonic anhydrases, but this is better viewed as a mechanistic side branch than the main oncology rationale for celecoxib itself
11 Clinical Translation Constraint Overall efficacy signal mixed; biomarker-defined benefit more plausible than broad use Cardiovascular, renal, GI, and drug-interaction liabilities constrain chronic escalation G Limits generalized oncology deployment Main constraint is that clinically achievable exposure strongly supports COX-2/PGE2 modulation, whereas many direct cytotoxic claims require higher concentrations; major adjuvant trials were negative overall, though PIK3CA-activated colon cancer is a notable exception signal

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
MRP1, Multidrug Resistance Protein 1: Click to Expand ⟱
Source:
Type:
Multidrug resistance protein 1 (MRP1) encoded by ABCC1.
MRP1 levels are elevated in numerous cancer types, NSCLC, breast cancer, and prostate cancer Multidrug Resistance Protein 1 (MDR1), also known as P-glycoprotein (P-gp) or ABCB1, is a membrane protein that functions as an efflux pump, transporting a variety of drugs and xenobiotics out of cells. Its expression is a significant factor in the development of multidrug resistance (MDR) in cancer therapy.

Resistance Protein 1 (MDR1) is often upregulated in various cancers, and its high expression is associated with poor prognosis and protumorigenic effects due to its role in drug resistance.
Scientific Papers found: Click to Expand⟱
5965- CEL,  Cisplatin,    Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway
- in-vitro, OS, MG63
COX2↓, ChemoSen↑, MDR1↓, MRP1↓, E-cadherin↓, β-catenin/ZEB1↓, Apoptosis↑, TumCCA↑, TumCG↓, P-gp↓, PI3K↓, Akt↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,   TumCG↓, 1,  

Migration ⓘ

E-cadherin↓, 1,   β-catenin/ZEB1↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   MDR1↓, 1,   MRP1↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: MRP1, Multidrug Resistance Protein 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:4  Target#:424  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page